Navigation Links
Alchem International Commits to Tropane Alkaloid APIs and Extends Production and Regulatory Support to Resolve Supply Gap

GENEVA, September 15, 2014 /PRNewswire/ --

Following the decision by the principal European manufacturers to exit or end market development and regulatory support for the niche range of Tropane Alkaloid APIs (active pharmaceutical ingredients) - including Atropine, Atropine Sulfate, Tropine, Nortropine, Homatropine Methylbromide, Homatropine Hydrobromide, Digoxin and Cimetropium Bromide - Alchem International ( has confirmed commitment to maintain production and regulatory (Drug Master File) support from its GMP production units.


Raman Mehta, CEO and President at Alchem International, commented, "Whilst the tropane alkaloid family of APIs is a specialist business and difficult to manage within larger scale production facilities, Alchem International has invested in a suite of bespoke manufacturing and regulatory capabilities to support smaller scale, as well as, large scale API production and dossier support. 

Mr Mehta continued, "At short notice, Alchem International's R&D and regulatory teams have worked against the clock to provide a solution to our partner customers to resolve the supply gap and consequentially a potential withdrawal of these medicines from the market. This has been a significant undertaking and one we are proud to make, because we understand that, for customers, consistent supply of all APIs is vital, not only the mainstream ones."

Alchem International will be participating at CPHI Worldwide 2014 in Paris, the world's leading pharmaceutical networking event, from the 6th of October 2014 to the 9th October, at stand 6T55 

About Alchem International

Alchem International is a family-owned company, founded in 1935. A pioneer in phytochemicals, it has nearly 80 years' experience in supplying plant-derived active ingredients to the pharmaceutical, nutraceutical and cosmetics industries worldwide. Alchem International employs 1,100 people across its four international divisions in India, Europe, the United States and Hong Kong. Alchem operates WHO and FDA GMP approved manufacturing sites in India, which export 90% of their production volumes. The company has 18 DMF dossiers with filings in over 20 countries worldwide.  In addition to tropane alkaloids key products include Calcium sennosides, Colchicine, Enoxolone, Hysocine-N-Butylbromide, Nicotine, Thiocolchicoside and Vinpocetine.


Media contact
Robin Ward
Position. Business Development Director - Alchem International SA (Europe).
Tel. +41-91-604-6921
Mobile. +41-79-682-6621

SOURCE Alchem International
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Alchem International sengage à poursuivre et étendre la production des principes pharmaceutiques actifs contenant des alcaloïdes tropaniques et à soutenir la réglementation pour combler lécart dapprovisionnement
2. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
5. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
6. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
7. Chindex International, Inc. to Report First Quarter 2012 Financial Results
8. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
9. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
10. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
11. Bacterin International Signs Its Third National GPO Contract with Novation
Post Your Comments:
(Date:6/18/2019)... , ... June 18, 2019 , ... ... in Los Angeles County. The office is located at 50 Bellefontaine Street, Suite ... equipment plus all of the top-notch care already offered in all of their ...
(Date:6/18/2019)... ... 2019 , ... The dentists of DiBartola Dental are providing ... area. Understanding the crippling effects patients experience when it comes to dental anxiety, ... same-day oral sedation, nitrous oxide, and IV sedation at their practice. By combining ...
(Date:6/16/2019)... ... June 15, 2019 , ... Dr. Brian ... state-of-the-art treatment with cutting-edge technology, has opened. , The clinic is offering ... capabilities of regenerative medicine. , “Using the remarkable cutting-edge technology of stem ...
Breaking Medicine Technology:
(Date:6/20/2019)... (PRWEB) , ... June 20, 2019 , ... ... to announce their partnership with Physical Therapy Solutions in Lawton, which has joined ... the clinic is the group’s 28th clinic in the state. , Physical ...
(Date:6/19/2019)... ... June 19, 2019 , ... The Clean ... in 2018 by the Alliance and its partners. Under the theme “Investment. Innovation. ... across the clean cooking sector, including an entrepreneur and manufacturer in Africa, a ...
(Date:6/19/2019)... ... 2019 , ... Ovation® Fertility scientists have been invited to present four pieces ... Annual Meeting in Vienna, June 23-26, 2019. , Ovation’s oral presentation about the ... Basic Science Award for Oral Presentation and the Fertility Society of Australia Exchange Award., ...
(Date:6/18/2019)... ... June 18, 2019 , ... ... today announced Steve Einig has joined the organization in the newly created role ... initiatives around market engagement, marketing, strategic events and brand management. , “Steve brings ...
(Date:6/14/2019)... ... June 14, 2019 , ... United Breast Cancer ... scheduled for Saturday, July 13th. UBCF is thrilled to return to the “City ... breast cancer. This second event was added after an overwhelming response to the ...
Breaking Medicine News(10 mins):